---
title: 'Asciminib Monotherapy as Frontline Treatment of Chronic-Phase Chronic Myeloid
  Leukemia: Results from the ASCEND Study'
date: '2024-08-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39102630/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240806181134&v=2.18.0.post9+e462414
source: Blood
description: Asciminib is a myristoyl site BCR::ABL1 inhibitor approved for chronic
  phase chronic myeloid leukaemia (CP-CML) patients failing ≥2 prior lines of therapy.
  The Australasian Leukaemia & Lymphoma Group (ALLG) conducted the ASCEND study to
  assess efficacy of asciminib for newly-diagnosed CP-CML. Patients commenced asciminib
  40 mg twice daily (BID) and thereafter were managed according to molecular milestones.
  Patients with treatment failure, defined as BCR::ABL1 >10% (IS) at 3 or 6 months,
  or ...
disable_comments: true
---
Asciminib is a myristoyl site BCR::ABL1 inhibitor approved for chronic phase chronic myeloid leukaemia (CP-CML) patients failing ≥2 prior lines of therapy. The Australasian Leukaemia & Lymphoma Group (ALLG) conducted the ASCEND study to assess efficacy of asciminib for newly-diagnosed CP-CML. Patients commenced asciminib 40 mg twice daily (BID) and thereafter were managed according to molecular milestones. Patients with treatment failure, defined as BCR::ABL1 >10% (IS) at 3 or 6 months, or ...